To explore the relationship between intrauterine device (IUD) use and risk of ovarian cancer through systematic review of the literature and meta-analysis.
We searched MEDLINE, EMBASE, Cochrane Library, Web of Science Core Collection from inception to June 2018. For the MEDLINE search, we included the MeSH terms “intrauterine devices” AND “ovarian neoplasms,” however also searching “intrauter*,” “ovar*” and “fallopian tube,” as well as “cancer” and “carcinoma” as keywords to include all possible variations. Similar search terms were used in the other databases. We also searched ClinicalTrials.gov.
Case–control and cohort studies that collected individual level data on IUD use and ovarian cancer diagnosis were critically reviewed and data extracted. Review of abstracts from 399 articles through systematic database review and an additional 200 articles through Google Scholar identified a total of 15 studies with individual level data regarding IUD use and incident ovarian cancer. On critical review, 11 of these studies were used for meta-analysis. All case reports and reviews were excluded.
The data were harmonized and weighted and summary odds ratios (ORs) were calculated. Covariates were identified evaluated separately. A random-effects meta-analysis was performed to confirm minimal bias. Harmonization and weighting of the data revealed an OR association between ever use of an IUD and incident ovarian cancer to be 0.68 (95% CI 0.62–0.75). There were no significant differences found between covariates. Heterogeneity among all studies was found to be I2=68%.
Intrauterine device use is associated with a reduced incidence of ovarian cancer based on a review of existing retrospective data. Unfortunately, prospective investigation into the role of IUDs in ovarian cancer prevention is limited.
A systematic review and meta-analysis of retrospective data reveals that intrauterine device use is associated with a reduced incidence of ovarian cancer.
Divisions of Gynecologic Oncology and Family Planning, Department of Obstetrics and Gynecology, and the Health Sciences Library, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
Corresponding author: Saketh R. Guntupalli, MD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO; email: Saketh.Guntupalli@ucdenver.edu.
Financial Disclosure Kristen Desanto disclosed money has been paid to her from University of Colorado Anschutz Medical Campus (employment), Medical Library Association (payment for educational presentation), and the Georgia Health Sciences Library Association (payment for educational presentation). Her spouse is employed by Kaiser Permanente (Information Technology department). Stephanie Teal disclosed receiving a Society of Family Planning honorarium for being the Board President. She received funds from Merck and Co. for service on DSMB for an FDA-mandated phase 4 study and from Bayer Healthcare, Sebela, NICHD, and Medicines360 (these are for contraceptive research trials in her division). The other authors did not report any potential conflicts of interest.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at http://links.lww.com/AOG/B511.